← All companies

ACRV

Acrivon Therapeutics, Inc.

ACRV Nasdaq Pharmaceutical Preparations EDGAR ↗

$1.56

+0.04 +2.63%

Key statistics

from XBRL data in SEC filings

Market cap

$66.8M

Revenue (TTM)

—

Net income (TTM)

-$77.3M

EPS (TTM)

$-2.00

P/E ratio

—

Dividend yield

—

Free cash flow

-$65.3M

Cash

$34.1M

Total assets

$108M

Gross margin

—

52-week range

$1.20 – $3.56

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Director or officer change; Shareholder vote results Jun 17, 2026 10-Q Quarter ended 2026-03-31 May 13, 2026 8-K Results of operations (earnings release) May 13, 2026 8-K Results of operations (earnings release); Regulation FD disclosure Mar 19, 2026 10-K Fiscal year ended 2025-12-31 Mar 19, 2026 8-K Terminated a material agreement Mar 2, 2026 8-K Regulation FD disclosure Feb 27, 2026 8-K Regulation FD disclosure Jan 8, 2026 8-K Results of operations (earnings release); Regulation FD disclosure; Other events Jan 8, 2026 10-Q Quarter ended 2025-09-30 Nov 13, 2025 8-K Results of operations (earnings release) Nov 13, 2025 8-K Regulation FD disclosure Sep 5, 2025 10-Q Quarter ended 2025-06-30 Aug 13, 2025 8-K Results of operations (earnings release) Aug 13, 2025 8-K Shareholder vote results Jun 13, 2025 10-Q Quarter ended 2025-03-31 May 14, 2025 8-K Results of operations (earnings release) May 14, 2025 8-K Regulation FD disclosure Apr 7, 2025 8-K Regulation FD disclosure Mar 27, 2025 10-K Fiscal year ended 2024-12-31 Mar 27, 2025 8-K Results of operations (earnings release); Regulation FD disclosure; Other events Mar 25, 2025 8-K Director or officer change Mar 14, 2025 10-Q Quarter ended 2024-09-30 Nov 13, 2024 8-K Results of operations (earnings release) Nov 13, 2024 8-K Regulation FD disclosure; Other events Oct 11, 2024 8-K Regulation FD disclosure; Other events Sep 16, 2024 8-K Results of operations (earnings release) Aug 13, 2024 10-Q Quarter ended 2024-06-30 Aug 13, 2024 8-K Shareholder vote results Jun 21, 2024 8-K Results of operations (earnings release) May 14, 2024 10-Q Quarter ended 2024-03-31 May 14, 2024 8-K Results of operations (earnings release); Regulation FD disclosure; Other events Apr 24, 2024 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure Apr 9, 2024 8-K Results of operations (earnings release) Mar 28, 2024 10-K Fiscal year ended 2023-12-31 Mar 28, 2024 8-K Director or officer change Mar 4, 2024 8-K Director or officer change Feb 8, 2024 8-K Regulation FD disclosure Jan 8, 2024 8-K Entered a material agreement Dec 8, 2023 8-K Results of operations (earnings release); Regulation FD disclosure Nov 9, 2023